Clinical pharmacology of the tricyclic antidepressants.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to T A Ban.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A 6-week double-blind comparison of mianserin, a new antidepressant, and amitriptyline allowed us to explore the problem of demonstrating main effect differences in drug/drug trials when the focus is primarily only upon efficacy or upon common adverse symptomatology. Statistical analyses of standard psychiatric rating scales revealed no significant treatment differences, while both treatment groups exhibited significant parallel improvement across time. Examination of treatment emergent symptoms indicated that, while it evoked fewer anticholinergic symptoms than amitriptyline, mianserin exhibited a different profile of adverse symptomatology. The usefulness of a measure of the benefit/risk ratio was described as a means of clarifying drug/drug comparisons.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
An attempt to construct a psychophysiological (conditioning) classification of chronic schizophrenia has been reported and the relationship of this new classification with the prevailing clinical (psychopathological) classification has been examined. Our findings suggest that our chronic schizophrenic population may be described in terms of a hypothetical continuum, based on the combination of the 11 experimental variables tested. This is supported by the result that our experimental population was distributed over 97 of the possible 117 categories. Furthermore, in a Pavlovian frame of reference our population disperses into three groups: a high performance group, in which both, excitatory and inhibitory processes are relatively maintained, a moderate performance group with some impairment of the inhibitory process, and a low performance group in which both the excitatory and the inhibitory processes are relatively impaired. Heuristically even more important is the finding that these schizophrenic categories are characterized by dissociation, either within the individual functional system or between this functional systems. In most of the categories of the experimental population a characteristic dissociation of functioning appears. It is characterized by a relatively well maintained functional ability of the autonomic functional system in contrast to an impaired skeletomuscular system. This dissociation resembles the phenomenon of schizokinesis. Since the morphological substrates of our experimental variables are those which are also affected by a variety of psychoactive drugs with well defined neurophysiological action, the categories delineated in this study would be verified by differential psychopharmacological responsiveness.
Viloxazine, an aryl-oxypropanolamine type of beta-adreno-receptor antagonist, has been used in the treatment of depression. In a double-blind drug interaction study with flurazepam, a commonly used benzodiazepine hypnotic, viloxazine administered alone decreased the amount of time spent in REM sleep, increased the amount of time in the "light" stages of sleep, and increased the number of transitions to awake. However, no interactive effects of the combined administration of viloxazine and flurazepam could be detected.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.